KalVista Pharmaceuticals (KALV) is a small-cap pharmaceutical company seeking to develop and commercialize small molecule protease inhibitors to treat diseases with significant unmet need. The company's initial focus is on Hereditary Angioedema ((HAE)) and Diabetic Macular Edema ((DME)). The stock price is currently near 52-week low, while annual stockholders meeting is scheduled for October 2, 2019. We take a look at its investability on a member's request, although our IOMachine method is used to only review stocks with drugs having efficacy data, and this one doesn’t have a phase 2 trial yet.